This company develops antibody-based imaging and therapy technology to enhance cancer treatment efficacy. Their platform enables selective chemical manipulation of tagged antibodies in vivo, improving radioimmuno-imaging, therapy, and antibody-drug conjugates for more effective and lower-dose imaging.
Funding
$65M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GHYCFounders
Product
Problem
Conventional antibody-drug conjugates (ADCs) are limited by the availability of suitable internalizing targets on cancer cells, which are not universally expressed across all cancer types. This restricts the scope of treatable tumors and necessitates the discovery of new internalizing targets.
Solution
Tagworks Pharmaceuticals is developing Click-to-Release technology, an *in vivo* click chemistry platform designed to enhance the efficacy and reduce the toxicity of systemic cancer treatments. This technology enables controlled drug release induced by an *in vivo* click reaction with a trigger molecule, expanding the ADC target scope to include non- or poorly internalizing receptors and markers. The platform facilitates on-target activation of ADCs and immunomodulators within the tumor microenvironment, as well as off-target deactivation of circulating radiopharmaceuticals. Their lead program, TGW101, is a click-cleavable ADC targeting TAG72, a clinically validated non-internalizing target widely expressed in solid tumors.
Target Audience
The primary target audience includes oncology researchers and clinicians seeking to improve cancer treatment efficacy and reduce toxicity, as well as pharmaceutical companies developing novel ADC therapies.
Features
- *In vivo* click chemistry for controlled drug release.
- Expansion of ADC target scope to non- or poorly internalizing receptors.
- On-target activation of ADCs and immunomodulators in the tumor microenvironment.
- Off-target deactivation of circulating radiopharmaceuticals to reduce toxicity.
- TGW101: a click-cleavable ADC targeting TAG72, a clinically validated non-internalizing target.